Abbott Laboratories (ABT) EV/EBITDA Ratio: 16.88x
Is Abbott Laboratories’s EV/EBITDA ratio high or low?
Abbott Laboratories's EV/EBITDA ratio of 16.88x is in line with its 5-year average of 18.58x, around the middle of its 5-year range (12.79x–23.30x).
The EV/EBITDA ratio for Abbott Laboratories (ABT) is 16.88x as of Wednesday, June 10, 2026. It is below its 12-month average by 9.84% (18.72x).
ABT EV/EBITDA Ratio Chart
ABT Average EV/EBITDA Ratio Chart
ABT Current vs Average EV/EBITDA Ratio Chart
ABT EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
16.88x
EV/EBITDA RATIO AVG TTM
18.72x
EV/EBITDA RATIO AVG 3Y
19.30x
EV/EBITDA RATIO AVG 5Y
18.58x
EV/EBITDA RATIO AVG 10Y
20.47x
EV/EBITDA RATIO AVG 15Y
17.83x
EV/EBITDA RATIO AVG 20Y
15.08x
CURRENT VS TTM AVG
-9.84%
CURRENT VS 3Y AVG
-12.52%
CURRENT VS 5Y AVG
-9.14%
CURRENT VS 10Y AVG
-17.55%
CURRENT VS 15Y AVG
-5.32%
CURRENT VS 20Y AVG
+11.90%
ABT Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | $154.66B | 16.88x | 18.72x | 19.30x | 18.58x |
| Gilead Sciences, Inc. (GILD) | $151.21B | 12.54x | 14.17x | 17.98x | 15.97x |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 39.06x | 52.49x | 59.81x | 55.90x |
| Pfizer Inc. (PFE) | $146.36B | 12.38x | 10.50x | 15.94x | 13.74x |
| Danaher Corporation (DHR) | $130.25B | 21.52x | 23.46x | 23.88x | 22.36x |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 19.72x | 19.74x | 20.47x | 20.32x |
| Amgen Inc. (AMGN) | $183.75B | 13.28x | 13.25x | 14.20x | 13.96x |
| CVS Health Corporation (CVS) | $125.16B | 17.45x | 14.88x | 11.86x | 12.00x |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 10.82x | 9.64x | 16.60x | 15.48x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 20.92x | 22.99x | 82.30x | 54.94x |
EV/EBITDA vs. its own history
At 16.9, EV/EBITDA is in its normal range — richer than 51% of its 20-year range.
20-year low
4.3
median
16.6
20-year high
31.3
Understanding EV/EBITDA
Enterprise Value (EV) = Market Cap + Total Debt - Cash
EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization
EV/EBITDA is commonly used for comparing companies because:
- It accounts for debt levels (capital structure neutral)
- It removes effects of different depreciation policies
- It can be compared across countries with different tax rates
- It can remain available when net income is negative, if EBITDA is positive
Abbott Laboratories EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Abbott Laboratories (ABT)?
- The EV/EBITDA ratio for ABT stock is 16.88x.
- Is Abbott Laboratories's EV/EBITDA ratio high or low?
- Abbott Laboratories's EV/EBITDA ratio of 16.88x is in line with its 5-year average of 18.58x, around the middle of its 5-year range (12.79x–23.30x).
- What is the TTM average EV/EBITDA ratio for Abbott Laboratories (ABT)?
- The TTM average EV/EBITDA ratio for ABT stock is 18.72x.
- What is the 3Y average EV/EBITDA ratio for Abbott Laboratories (ABT)?
- The 3Y average EV/EBITDA ratio for ABT stock is 19.30x.
- What is the 5Y average EV/EBITDA ratio for Abbott Laboratories (ABT)?
- The 5Y average EV/EBITDA ratio for ABT stock is 18.58x.
- What is the 10Y average EV/EBITDA ratio for Abbott Laboratories (ABT)?
- The 10Y average EV/EBITDA ratio for ABT stock is 20.47x.
- What is the 15Y average EV/EBITDA ratio for Abbott Laboratories (ABT)?
- The 15Y average EV/EBITDA ratio for ABT stock is 17.83x.
- What is the 20Y average EV/EBITDA ratio for Abbott Laboratories (ABT)?
- The 20Y average EV/EBITDA ratio for ABT stock is 15.08x.
Abbott Laboratories EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-10 | 16.88x |
| 2026-06-09 | 17.28x |
| 2026-06-08 | 17.16x |
| 2026-06-05 | 17.25x |
| 2026-06-04 | 17.20x |
| 2026-06-03 | 16.59x |
| 2026-06-02 | 16.58x |
| 2026-06-01 | 16.72x |
| 2026-05-29 | 16.36x |
| 2026-05-28 | 16.48x |
| 2026-05-27 | 16.38x |
| 2026-05-26 | 16.54x |
| 2026-05-22 | 16.66x |
| 2026-05-21 | 16.71x |
| 2026-05-20 | 16.81x |
| 2026-05-19 | 16.88x |
| 2026-05-18 | 16.74x |
| 2026-05-15 | 16.18x |
| 2026-05-14 | 16.25x |
| 2026-05-13 | 16.08x |
| 2026-05-12 | 16.16x |
| 2026-05-11 | 15.87x |
| 2026-05-08 | 16.16x |
| 2026-05-07 | 16.59x |
| 2026-05-06 | 16.48x |
| 2026-05-05 | 16.62x |
| 2026-05-04 | 16.68x |
| 2026-05-01 | 16.99x |
| 2026-04-30 | 17.20x |
| 2026-04-29 | 17.29x |
| 2026-04-28 | 14.66x |
| 2026-04-27 | 14.50x |
| 2026-04-24 | 14.25x |
| 2026-04-23 | 14.45x |
| 2026-04-22 | 14.34x |
| 2026-04-21 | 14.49x |
| 2026-04-20 | 14.98x |
| 2026-04-17 | 15.11x |
| 2026-04-16 | 14.90x |
| 2026-04-15 | 15.82x |
| 2026-04-14 | 15.74x |
| 2026-04-13 | 15.69x |
| 2026-04-10 | 15.63x |
| 2026-04-09 | 15.99x |
| 2026-04-08 | 16.12x |
| 2026-04-07 | 15.86x |
| 2026-04-06 | 15.93x |
| 2026-04-02 | 16.02x |
| 2026-04-01 | 15.94x |
| 2026-03-31 | 15.99x |
| 2026-03-30 | 15.87x |
| 2026-03-27 | 16.18x |
| 2026-03-26 | 16.27x |
| 2026-03-25 | 16.31x |
| 2026-03-24 | 16.19x |
| 2026-03-23 | 16.31x |
| 2026-03-20 | 16.40x |
| 2026-03-19 | 16.66x |
| 2026-03-18 | 16.86x |
| 2026-03-17 | 17.19x |
| 2026-03-16 | 17.08x |
| 2026-03-13 | 16.79x |
| 2026-03-12 | 16.80x |
| 2026-03-11 | 17.12x |
| 2026-03-10 | 17.17x |
| 2026-03-09 | 17.48x |
| 2026-03-06 | 17.02x |
| 2026-03-05 | 17.24x |
| 2026-03-04 | 17.55x |
| 2026-03-03 | 17.63x |
| 2026-03-02 | 17.71x |
| 2026-02-27 | 18.04x |
| 2026-02-26 | 18.03x |
| 2026-02-25 | 17.80x |
| 2026-02-24 | 17.77x |
| 2026-02-23 | 17.88x |
| 2026-02-20 | 17.42x |
| 2026-02-19 | 17.09x |
| 2026-02-18 | 17.26x |
| 2026-02-17 | 17.10x |
| 2026-02-13 | 17.17x |
| 2026-02-12 | 16.99x |
| 2026-02-11 | 17.30x |
| 2026-02-10 | 17.11x |
| 2026-02-09 | 16.93x |
| 2026-02-06 | 16.89x |
| 2026-02-05 | 16.63x |
| 2026-02-04 | 16.50x |
| 2026-02-03 | 16.62x |
| 2026-02-02 | 16.68x |
| 2026-01-30 | 16.66x |
| 2026-01-29 | 16.19x |
| 2026-01-28 | 16.18x |
| 2026-01-27 | 16.51x |
| 2026-01-26 | 16.59x |
| 2026-01-23 | 16.39x |
| 2026-01-22 | 16.56x |
| 2026-01-21 | 18.36x |
| 2026-01-20 | 18.42x |
| 2026-01-16 | 18.51x |
| 2026-01-15 | 18.77x |
| 2026-01-14 | 18.99x |
| 2026-01-13 | 18.89x |
| 2026-01-12 | 18.94x |
| 2026-01-09 | 19.13x |
| 2026-01-08 | 19.17x |
| 2026-01-07 | 19.29x |
| 2026-01-06 | 19.41x |
| 2026-01-05 | 19.21x |
| 2026-01-02 | 18.87x |
| 2025-12-31 | 19.04x |
| 2025-12-30 | 19.11x |
| 2025-12-29 | 18.93x |
| 2025-12-26 | 18.97x |
| 2025-12-24 | 18.96x |
| 2025-12-23 | 18.92x |
| 2025-12-22 | 19.02x |
| 2025-12-19 | 19.06x |
| 2025-12-18 | 19.01x |
| 2025-12-17 | 19.25x |
| 2025-12-16 | 19.27x |
| 2025-12-15 | 19.51x |
| 2025-12-12 | 19.06x |
| 2025-12-11 | 18.74x |
| 2025-12-10 | 18.63x |
| 2025-12-09 | 18.44x |
| 2025-12-08 | 18.56x |
| 2025-12-05 | 19.00x |
| 2025-12-04 | 19.05x |
| 2025-12-03 | 19.04x |
| 2025-12-02 | 19.19x |
| 2025-12-01 | 19.44x |
| 2025-11-28 | 19.57x |
| 2025-11-26 | 19.52x |
| 2025-11-25 | 19.44x |
| 2025-11-24 | 19.32x |
| 2025-11-21 | 19.45x |
| 2025-11-20 | 18.84x |
| 2025-11-19 | 19.16x |
| 2025-11-18 | 19.73x |
| 2025-11-17 | 19.74x |
| 2025-11-14 | 19.82x |
| 2025-11-13 | 19.62x |
| 2025-11-12 | 19.56x |
| 2025-11-11 | 19.29x |
| 2025-11-10 | 19.12x |
| 2025-11-07 | 19.19x |
| 2025-11-06 | 18.99x |
| 2025-11-05 | 18.92x |
| 2025-11-04 | 19.11x |
| 2025-11-03 | 18.82x |
| 2025-10-31 | 18.79x |
| 2025-10-30 | 18.94x |
| 2025-10-29 | 18.91x |
| 2025-10-28 | 19.65x |
| 2025-10-27 | 19.74x |
| 2025-10-24 | 19.69x |
| 2025-10-23 | 19.61x |
| 2025-10-22 | 19.85x |
| 2025-10-21 | 19.79x |
| 2025-10-20 | 20.09x |
| 2025-10-17 | 19.94x |
| 2025-10-16 | 19.80x |
| 2025-10-15 | 20.08x |
| 2025-10-14 | 20.65x |
| 2025-10-13 | 20.37x |
| 2025-10-10 | 20.55x |
| 2025-10-09 | 20.66x |
| 2025-10-08 | 20.81x |
| 2025-10-07 | 20.62x |
| 2025-10-06 | 20.73x |
| 2025-10-03 | 20.85x |
| 2025-10-02 | 20.61x |
| 2025-10-01 | 20.68x |
| 2025-09-30 | 20.76x |
| 2025-09-29 | 20.63x |
| 2025-09-26 | 20.70x |
| 2025-09-25 | 20.66x |
| 2025-09-24 | 20.75x |
| 2025-09-23 | 21.05x |
| 2025-09-22 | 21.16x |
| 2025-09-19 | 21.07x |
| 2025-09-18 | 20.85x |
| 2025-09-17 | 20.79x |
| 2025-09-16 | 20.58x |
| 2025-09-15 | 20.36x |
| 2025-09-12 | 20.72x |
| 2025-09-11 | 20.56x |
| 2025-09-10 | 20.07x |
| 2025-09-09 | 20.46x |
| 2025-09-08 | 20.49x |
| 2025-09-05 | 20.60x |
| 2025-09-04 | 20.59x |
| 2025-09-03 | 20.49x |
| 2025-09-02 | 20.38x |
| 2025-08-29 | 20.56x |
| 2025-08-28 | 20.37x |
| 2025-08-27 | 20.38x |
| 2025-08-26 | 20.40x |
| 2025-08-25 | 20.44x |
| 2025-08-22 | 20.55x |
| 2025-08-21 | 20.46x |
| 2025-08-20 | 20.53x |
| 2025-08-19 | 20.35x |
| 2025-08-18 | 20.20x |
| 2025-08-15 | 20.43x |
| 2025-08-14 | 20.05x |
| 2025-08-13 | 20.07x |
| 2025-08-12 | 20.32x |
| 2025-08-11 | 20.37x |
| 2025-08-08 | 20.81x |
| 2025-08-07 | 20.47x |
| 2025-08-06 | 20.30x |
| 2025-08-05 | 20.27x |
| 2025-08-04 | 20.15x |
| 2025-08-01 | 19.75x |
| 2025-07-31 | 19.59x |
| 2025-07-30 | 19.94x |
| 2025-07-29 | 20.67x |
| 2025-07-28 | 20.41x |
| 2025-07-25 | 20.44x |
| 2025-07-24 | 20.30x |
| 2025-07-23 | 20.33x |
| 2025-07-22 | 20.31x |
| 2025-07-21 | 20.11x |
| 2025-07-18 | 19.99x |
| 2025-07-17 | 19.50x |
| 2025-07-16 | 21.26x |
| 2025-07-15 | 21.22x |
| 2025-07-14 | 21.30x |
| 2025-07-11 | 21.30x |
| 2025-07-10 | 21.55x |
| 2025-07-09 | 21.49x |
| 2025-07-08 | 21.51x |
| 2025-07-07 | 21.56x |
| 2025-07-03 | 21.68x |
| 2025-07-02 | 21.63x |
| 2025-07-01 | 21.97x |
| 2025-06-30 | 21.93x |
| 2025-06-27 | 21.67x |
| 2025-06-26 | 21.56x |
| 2025-06-25 | 22.14x |
| 2025-06-24 | 22.25x |
| 2025-06-23 | 21.50x |
| 2025-06-20 | 21.45x |
| 2025-06-18 | 21.36x |
| 2025-06-17 | 21.34x |
| 2025-06-16 | 21.61x |
| 2025-06-13 | 21.87x |
| 2025-06-12 | 22.00x |
| 2025-06-11 | 21.81x |
| 2025-06-10 | 21.63x |
| 2025-06-09 | 21.52x |
| 2025-06-06 | 21.55x |
| 2025-06-05 | 21.60x |
| 2025-06-04 | 21.45x |
| 2025-06-03 | 21.57x |
| 2025-06-02 | 21.54x |
| 2025-05-30 | 21.55x |
| 2025-05-29 | 21.43x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford